{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T00:08:40Z","timestamp":1771459720092,"version":"3.50.1"},"reference-count":103,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,6]]},"DOI":"10.1097\/med.0000000000000065","type":"journal-article","created":{"date-parts":[[2014,4,9]],"date-time":"2014-04-09T10:09:05Z","timestamp":1397038145000},"page":"202-208","source":"Crossref","is-referenced-by-count":14,"title":["Testosterone and cardiovascular disease"],"prefix":"10.1097","volume":"21","author":[{"given":"C. Mary","family":"Schooling","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-9-20211004","doi-asserted-by":"crossref","first-page":"e5469","DOI":"10.1136\/bmj.e5469","article-title":"Many men are receiving unnecessary testosterone prescriptions.","volume":"345","author":"Gan","year":"2012","journal-title":"BMJ"},{"key":"R2-9-20211004","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1001\/jamainternmed.2013.6895","article-title":"Trends in androgen prescribing in the United States, 2001 to 2011.","volume":"173","author":"Baillargeon","year":"2013","journal-title":"JAMA Intern Med"},{"key":"R4-9-20211004","doi-asserted-by":"crossref","first-page":"548","DOI":"10.5694\/mja13.10111","article-title":"Global trends in testosterone prescribing, 2010-2011: expanding the spectrum of prescription drug misuse.","volume":"199","author":"Handelsman","year":"2013","journal-title":"Med J Aust"},{"key":"R5-9-20211004","doi-asserted-by":"crossref","first-page":"2536","DOI":"10.1210\/jc.2009-2354","article-title":"Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline.","volume":"95","author":"Bhasin","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"R6-9-20211004","doi-asserted-by":"crossref","first-page":"194","DOI":"10.3322\/caac.20061","article-title":"Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology.","volume":"60","author":"Levine","year":"2010","journal-title":"CA Cancer J Clin"},{"key":"R7-9-20211004","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1056\/NEJM200006223422506","article-title":"A comparison of observational studies and randomized, controlled trials.","volume":"342","author":"Benson","year":"2000","journal-title":"N Engl J Med"},{"key":"R8-9-20211004","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1056\/NEJM200006223422507","article-title":"Randomized, controlled trials, observational studies, and the hierarchy of research designs.","volume":"342","author":"Concato","year":"2000","journal-title":"N Engl J Med"},{"key":"R9-9-20211004","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.jclinepi.2012.11.005","article-title":"Observational studies often make clinical practice recommendations: an empirical evaluation of authors attitudes.","volume":"66","author":"Prasad","year":"2013","journal-title":"J Clin Epidemiol"},{"key":"R10-9-20211004","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1093\/ije\/dyh192","article-title":"Commentary: hormone replacement therapy and coronary heart disease: four lessons.","volume":"33","author":"Petitti","year":"2004","journal-title":"Int J Epidemiol"},{"key":"R11-9-20211004","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1001\/jama.2013.278040","article-title":"Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Womens Health Initiative randomized trials.","volume":"310","author":"Manson","year":"2013","journal-title":"JAMA"},{"key":"R12-9-20211004","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/0039-128X(90)90058-J","article-title":"Sex hormones and coronary disease: a review of the clinical studies.","volume":"55","author":"Kalin","year":"1990","journal-title":"Steroids"},{"key":"R13-9-20211004","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1016\/S0140-6736(97)11321-6","article-title":"Myth and paradox of coronary risk and the menopause.","volume":"351","author":"Tunstall-Pedoe","year":"1998","journal-title":"Lancet"},{"key":"R14-9-20211004","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1161\/01.CIR.95.1.252","article-title":"Sex differences in coronary heart disease. Why are women so superior The 1995 Ancel Keys Lecture.","volume":"95","author":"Barrett-Connor","year":"1997","journal-title":"Circulation"},{"key":"R15-9-20211004","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1001\/jama.1973.03230060030009","article-title":"5-mg day estrogen group. The coronary Drug Project Research Group.","volume":"226","year":"1973","journal-title":"JAMA"},{"key":"R17-9-20211004","doi-asserted-by":"crossref","first-page":"6516","DOI":"10.1210\/jc.2005-1077","article-title":"Mortality in patients with Klinefelter syndrome in Britain: a cohort study.","volume":"90","author":"Swerdlow","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"R18-9-20211004","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1007\/s10654-005-2150-0","article-title":"All-cause mortality and mortality of myocardial infarction for 989 legally castrated men.","volume":"20","author":"Eyben","year":"2005","journal-title":"Eur J Epidemiol"},{"key":"R19-9-20211004","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1210\/jc.2012-2382","article-title":"Clinical review: Klinefelter syndrome - a clinical update.","volume":"98","author":"Groth","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"R20-9-20211004","doi-asserted-by":"crossref","first-page":"2430","DOI":"10.1210\/jc.2010-3012","article-title":"Reference ranges for testosterone in men generated using liquid chromatography tandem mass spectrometry in a community-based sample of healthy nonobese young men in the Framingham Heart Study and applied to three geographically distinct cohorts.","volume":"96","author":"Bhasin","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"R21-9-20211004","doi-asserted-by":"crossref","first-page":"R47","DOI":"10.1530\/JOE-12-0582","article-title":"Testosterone: a vascular hormone in health and disease.","volume":"217","author":"Kelly","year":"2013","journal-title":"J Endocrinol"},{"key":"R22-9-20211004","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1353\/dem.0.0000","article-title":"Trends in U.S. adult chronic disease mortality, 1960-1999: age, period, and cohort variations.","volume":"45","author":"Yang","year":"2008","journal-title":"Demography"},{"key":"R23-9-20211004","doi-asserted-by":"crossref","first-page":"3007","DOI":"10.1210\/jc.2011-1137","article-title":"Clinical review: endogenous testosterone and mortality in men: a systematic review and meta-analysis.","volume":"96","author":"Araujo","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"R24-9-20211004","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1136\/hrt.2010.210757","article-title":"Endogenous testosterone and cardiovascular disease in healthy men: a meta-analysis.","volume":"97","author":"Ruige","year":"2011","journal-title":"Heart"},{"key":"R25-9-20211004","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1097\/COC.0b013e318201a406","article-title":"Prostate cancer, androgen deprivation therapy, obesity, the metabolic syndrome, type 2 diabetes, and cardiovascular disease: a review.","volume":"35","author":"Collier","year":"2012","journal-title":"Am J Clin Oncol"},{"key":"R26-9-20211004","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1001\/archinte.167.12.1252","article-title":"Sex steroids and all-cause and cause-specific mortality in men.","volume":"167","author":"Araujo","year":"2007","journal-title":"Arch Intern Med"},{"key":"R27-9-20211004","doi-asserted-by":"crossref","first-page":"E9","DOI":"10.1210\/jc.2013-3272","article-title":"In older men an optimal plasma testosterone is associated with reduced all-cause mortality and higher dihydrotestosterone with reduced ischemic heart disease mortality, while estradiol levels do not predict mortality.","volume":"99","author":"Yeap","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"R28-9-20211004","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.maturitas.2013.04.012","article-title":"A J-shaped association between plasma testosterone and risk of ischemic arterial event in elderly men: the French 3C cohort study.","volume":"75","author":"Soisson","year":"2013","journal-title":"Maturitas"},{"key":"R29-9-20211004","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.2337\/diacare.27.5.1036","article-title":"Testosterone and sex hormone-binding globulin predict the metabolic syndrome and diabetes in middle-aged men.","volume":"27","author":"Laaksonen","year":"2004","journal-title":"Diabetes Care"},{"key":"R30-9-20211004","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1038\/hr.2010.43","article-title":"Association of low testosterone with metabolic syndrome and its components in middle-aged Japanese men.","volume":"33","author":"Akishita","year":"2010","journal-title":"Hypertens Res"},{"key":"R31-9-20211004","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.atherosclerosis.2012.02.020","article-title":"Relation of total and free testosterone and sex hormone-binding globulin with cardiovascular risk factors in men aged 24-45 years. The Cardiovascular Risk in Young Finns Study.","volume":"222","author":"Firtser","year":"2012","journal-title":"Atherosclerosis"},{"key":"R32-9-20211004","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1097\/MED.0b013e32835edb71","article-title":"The effect of androgens on lipids.","volume":"20","author":"Monroe","year":"2013","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"R34-9-20211004","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1016\/j.metabol.2010.12.014","article-title":"Bioactive androgens and glucuronidated androgen metabolites are associated with subcutaneous and ectopic skeletal muscle adiposity among older black men.","volume":"60","author":"Miljkovic","year":"2011","journal-title":"Metabolism"},{"key":"R35-9-20211004","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.jsbmb.2012.02.005","article-title":"The differences between aromatizable and nonaromatizable androgens in relation to body composition and metabolic syndrome risk factors in men.","volume":"132","author":"Pospisilova","year":"2012","journal-title":"J Steroid Biochem Mol Biol"},{"key":"R36-9-20211004","doi-asserted-by":"crossref","first-page":"4130","DOI":"10.1210\/jc.2007-0252","article-title":"Androgens and glucuronidated androgen metabolites are associated with metabolic risk factors in men.","volume":"92","author":"Vandenput","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"R37-9-20211004","doi-asserted-by":"crossref","first-page":"S34","DOI":"10.1016\/j.juro.2012.11.017","article-title":"Metabolic complications of androgen deprivation therapy for prostate cancer.","volume":"189","author":"Saylor","year":"2013","journal-title":"J Urol"},{"key":"R38-9-20211004","doi-asserted-by":"crossref","first-page":"3979","DOI":"10.1200\/JCO.2006.05.9741","article-title":"Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy.","volume":"24","author":"Braga-Basaria","year":"2006","journal-title":"J Clin Oncol"},{"key":"R39-9-20211004","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1002\/cncr.23440","article-title":"Metabolic changes during gonadotropin-releasing hormone agonist therapy for prostate cancer: differences from the classic metabolic syndrome.","volume":"112","author":"Smith","year":"2008","journal-title":"Cancer"},{"key":"R40-9-20211004","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1158\/1055-9965.EPI-06-0792","article-title":"Reproducibility of serum sex steroid assays in men by RIA and mass spectrometry.","volume":"16","author":"Hsing","year":"2007","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"R41-9-20211004","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1530\/EJE-13-0222","article-title":"Testosterone and cardiometabolic risk in the general population - the impact of measurement method on risk associations: a comparative study between immunoassay and mass spectrometry.","volume":"169","author":"Haring","year":"2013","journal-title":"Eur J Endocrinol"},{"key":"R42-9-20211004","doi-asserted-by":"crossref","first-page":"247","DOI":"10.3109\/13685538.2010.487553","article-title":"Prevalence, incidence and risk factors of testosterone deficiency in a population-based cohort of men: results from the study of health in Pomerania.","volume":"13","author":"Haring","year":"2010","journal-title":"Aging Male"},{"key":"R43-9-20211004","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1111\/j.1365-2265.2012.04432.x","article-title":"Serum testosterone, dihydrotestosterone and estradiol concentrations in older men self-reporting very good health: the healthy man study.","volume":"77","author":"Sartorius","year":"2012","journal-title":"Clin Endocrinol (Oxf)"},{"key":"R44-9-20211004","doi-asserted-by":"crossref","first-page":"3289","DOI":"10.1210\/jc.2012-3842","article-title":"Longitudinal changes in testosterone over five years in community-dwelling men.","volume":"98","author":"Shi","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"R46-9-20211004","first-page":"1491","article-title":"Prostate Cancer Trialists Collaborative Group.","volume":"355","year":"2000","journal-title":"Lancet"},{"key":"R47-9-20211004","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1056\/NEJMoa1207506","article-title":"Increased survival with enzalutamide in prostate cancer after chemotherapy.","volume":"367","author":"Scher","year":"2012","journal-title":"N Engl J Med"},{"key":"R48-9-20211004","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/S1470-2045(12)70379-0","article-title":"Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study.","volume":"13","author":"Fizazi","year":"2012","journal-title":"Lancet Oncol"},{"key":"R49-9-20211004","doi-asserted-by":"crossref","first-page":"495","DOI":"10.2310\/JIM.0b013e3182408567","article-title":"Human steroid biosynthesis for the oncologist.","volume":"60","author":"Auchus","year":"2012","journal-title":"J Investig Med"},{"key":"R50-9-20211004","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1097\/PPO.0b013e31827e0b6f","article-title":"Agents that target androgen synthesis in castration-resistant prostate cancer.","volume":"19","author":"Ferraldeschi","year":"2013","journal-title":"Cancer J"},{"key":"R51-9-20211004","doi-asserted-by":"crossref","first-page":"C113","DOI":"10.1016\/0303-7207(91)90116-A","article-title":"Intracrinology.","volume":"78","author":"Labrie","year":"1991","journal-title":"Mol Cell Endocrinol"},{"key":"R52-9-20211004","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.jsbmb.2008.11.004","article-title":"Comparable amounts of sex steroids are made outside the gonads in men and women: strong lesson for hormone therapy of prostate and breast cancer.","volume":"113","author":"Labrie","year":"2009","journal-title":"J Steroid Biochem Mol Biol"},{"key":"R53-9-20211004","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1172\/JCI106219","article-title":"Studies on testosterone metabolism in subjects with testicular feminization syndrome.","volume":"49","author":"Mauvais-Jarvis","year":"1970","journal-title":"J Clin Invest"},{"key":"R54-9-20211004","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1210\/jcem-59-3-417","article-title":"Origin of plasma androstanediol glucuronide in men.","volume":"59","author":"Moghissi","year":"1984","journal-title":"J Clin Endocrinol Metab"},{"key":"R55-9-20211004","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jsbmb.2006.02.004","article-title":"Androgen glucuronides, instead of testosterone, as the new markers of androgenic activity in women.","volume":"99","author":"Labrie","year":"2006","journal-title":"J Steroid Biochem Mol Biol"},{"key":"R56-9-20211004","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1359\/jbmr.061018","article-title":"Serum levels of specific glucuronidated androgen metabolites predict BMD and prostate volume in elderly men.","volume":"22","author":"Vandenput","year":"2007","journal-title":"J Bone Miner Res"},{"key":"R57-9-20211004","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1111\/eci.12174","article-title":"Androgen activity, ischaemic heart disease and risk factors among men in NHANES III.","volume":"43","author":"Schooling","year":"2013","journal-title":"Eur J Clin Invest"},{"key":"R58-9-20211004","doi-asserted-by":"crossref","first-page":"234","DOI":"10.2337\/dc06-1579","article-title":"Androgens and diabetes in men: results from the Third National Health and Nutrition Examination Survey (NHANES III).","volume":"30","author":"Selvin","year":"2007","journal-title":"Diabetes Care"},{"key":"R59-9-20211004","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1001\/jama.2013.280386","article-title":"Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels.","volume":"310","author":"Vigen","year":"2013","journal-title":"JAMA"},{"key":"R60-9-20211004","doi-asserted-by":"crossref","first-page":"e85805","DOI":"10.1371\/journal.pone.0085805","article-title":"Increased risk of nonfatal myocardial infarction following testosterone therapy prescription in men.","volume":"9","author":"Finkle","year":"2014","journal-title":"PLoS One"},{"key":"R61-9-20211004","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1002\/sim.3034","article-title":"Mendelian randomization: using genes as instruments for making causal inferences in epidemiology.","volume":"27","author":"Lawlor","year":"2008","journal-title":"Stat Med"},{"key":"R62-9-20211004","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1038\/aja.2013.71","article-title":"Mendelian randomization: loosening the Gordian knot of testosterone and male ageing.","volume":"15","author":"Handelsman","year":"2013","journal-title":"Asian J Androl"},{"key":"R63-9-20211004","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/j.2047-2927.2012.00002.x","article-title":"Mendelian randomization suggests noncausal associations of testosterone with cardiometabolic risk factors and mortality.","volume":"1","author":"Haring","year":"2013","journal-title":"Andrology"},{"key":"R64-9-20211004","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1093\/ije\/dyt239","article-title":"Genetically predicted testosterone and cardiovascular risk factors in men: a Mendelian randomization analysis in the Guangzhou Biobank Cohort Study.","volume":"43","author":"Zhao","year":"2014","journal-title":"Int J Epidemiol"},{"key":"R66-9-20211004","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1001\/jamainternmed.2013.7579","article-title":"Low t as in template: how to sell disease.","volume":"173","author":"Schwartz","year":"2013","journal-title":"JAMA Intern Med"},{"key":"R67-9-20211004","doi-asserted-by":"crossref","first-page":"650","DOI":"10.7326\/0003-4819-151-9-200911030-00150","article-title":"Oral phosphodiesterase-5 inhibitors and hormonal treatments for erectile dysfunction: a systematic review and meta-analysis.","volume":"151","author":"Tsertsvadze","year":"2009","journal-title":"Ann Intern Med"},{"key":"R68-9-20211004","doi-asserted-by":"crossref","first-page":"681","DOI":"10.7326\/0003-4819-157-10-201211200-00004","article-title":"Effect of testosterone replacement on response to sildenafil citrate in men with erectile dysfunction: a parallel, randomized trial.","volume":"157","author":"Spitzer","year":"2012","journal-title":"Ann Intern Med"},{"key":"R69-9-20211004","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1001\/archinternmed.2009.313","article-title":"Adverse events in randomized trials: neglected, restricted, distorted, and silenced.","volume":"169","author":"Ioannidis","year":"2009","journal-title":"Arch Intern Med"},{"key":"R70-9-20211004","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1093\/gerona\/60.11.1451","article-title":"Adverse events associated with testosterone replacement in middle-aged and older men: a meta-analysis of randomized, placebo-controlled trials.","volume":"60","author":"Calof","year":"2005","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"R71-9-20211004","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0025-6196(11)60964-6","article-title":"Testosterone and cardiovascular risk in men: a systematic review and meta-analysis of randomized placebo-controlled trials.","volume":"82","author":"Haddad","year":"2007","journal-title":"Mayo Clin Proc"},{"key":"R72-9-20211004","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1210\/jc.2009-2575","article-title":"Clinical review 1: Adverse effects of testosterone therapy in adult men: a systematic review and meta-analysis.","volume":"95","author":"Fernandez-Balsells","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"R73-9-20211004","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/1741-7015-11-108","article-title":"Testosterone and cardiovascular events among men: a systematic review and meta-analysis of placebo-controlled randomized trials.","volume":"11","author":"Xu","year":"2013","journal-title":"BMC Med"},{"key":"R74-9-20211004","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.jclinepi.2004.11.028","article-title":"Powering our way to the elusive side effect: a composite outcome basket of predefined designated endpoints in each organ system should be included in all controlled trials.","volume":"58","author":"Tugwell","year":"2005","journal-title":"J Clin Epidemiol"},{"key":"R75-9-20211004","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa1000485","article-title":"Adverse events associated with testosterone administration.","volume":"363","author":"Basaria","year":"2010","journal-title":"N Engl J Med"},{"key":"R76-9-20211004","first-page":"807","article-title":"The Copenhagen Study Group for Liver Diseases.","volume":"6","year":"1986","journal-title":"Hepatology"},{"key":"R77-9-20211004","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1146\/annurev.pa.33.040193.002433","article-title":"Cardiovascular toxicity of anabolic steroids.","volume":"33","author":"Rockhold","year":"1993","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"R78-9-20211004","doi-asserted-by":"crossref","first-page":"4300","DOI":"10.1210\/jc.2013-1970","article-title":"Beneficial and adverse effects of testosterone on the cardiovascular system in men.","volume":"98","author":"Ruige","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"R79-9-20211004","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1001\/jama.2011.1745","article-title":"Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials.","volume":"306","author":"Nguyen","year":"2011","journal-title":"JAMA"},{"key":"R80-9-20211004","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.eururo.2013.10.032","article-title":"Cardiovascular morbidity associated with gonadotropin releasing hormone agonists and an antagonist.","volume":"65","author":"Albertsen","year":"2014","journal-title":"Eur Urol"},{"key":"R81-9-20211004","first-page":"5","article-title":"Is the flare phenomenon clinically significant U","volume":"58","author":"Bubley","year":"2001","journal-title":"rology"},{"key":"R82-9-20211004","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1056\/NEJM199708213370806","article-title":"Discrepancies between meta-analyses and subsequent large randomized, controlled trials.","volume":"337","author":"LeLorier","year":"1997","journal-title":"N Engl J Med"},{"key":"R84-9-20211004","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1210\/jc.2012-3695","article-title":"Effects of testosterone and progressive resistance exercise in healthy, highly functioning older men with low-normal testosterone levels.","volume":"98","author":"Hildreth","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"R86-9-20211004","doi-asserted-by":"crossref","first-page":"828","DOI":"10.2337\/dc10-1233","article-title":"Testosterone replacement in hypogonadal men with type 2 diabetes andor metabolic syndrome (the TIMES2 study).","volume":"34","author":"Jones","year":"2011","journal-title":"Diabetes Care"},{"key":"R87-9-20211004","doi-asserted-by":"crossref","first-page":"146","DOI":"10.4103\/1008-682X.122346","article-title":"Metabolic effects of testosterone replacement therapy on hypogonadal men with type 2 diabetes mellitus: A systematic review and meta-analysis of randomized controlled trials.","volume":"16","author":"Cai","year":"2014","journal-title":"Asian J Androl"},{"key":"R89-9-20211004","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1161\/CIRCHEARTFAILURE.111.965632","article-title":"Testosterone supplementation in heart failure: a meta-analysis.","volume":"5","author":"Toma","year":"2012","journal-title":"Circ Heart Fail"},{"key":"R90-9-20211004","doi-asserted-by":"crossref","first-page":"391576","DOI":"10.1155\/2011\/391576","article-title":"Metabolic complications and increased cardiovascular risks as a result of androgen deprivation therapy in men with prostate cancer.","volume":"2011","author":"Shastri","year":"2011","journal-title":"Prostate Cancer"},{"key":"R91-9-20211004","doi-asserted-by":"crossref","first-page":"49","DOI":"10.2147\/CMAR.S16893","article-title":"Cardiovascular risk during hormonal treatment in patients with prostate cancer.","volume":"3","author":"Van Poppel","year":"2011","journal-title":"Cancer Manag Res"},{"key":"R92-9-20211004","doi-asserted-by":"crossref","first-page":"e978","DOI":"10.1542\/peds.2010-1290","article-title":"Blood pressure percentiles by age and height from nonoverweight children and adolescents in Germany.","volume":"127","author":"Neuhauser","year":"2011","journal-title":"Pediatrics"},{"key":"R93-9-20211004","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1016\/j.clinbiochem.2006.06.012","article-title":"Pediatric reference intervals for lipids and apolipoproteins on the VITROS 5,1 FS Chemistry System.","volume":"39","author":"Yip","year":"2006","journal-title":"Clin Biochem"},{"key":"R94-9-20211004","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1001\/jamainternmed.2013.6892","article-title":"Promoting Low T: A Medical Writers Perspective.","volume":"173","author":"Braun","year":"2013","journal-title":"JAMA Intern Med"},{"key":"R95-9-20211004","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1111\/j.1749-6632.1968.tb53838.x","article-title":"Are gonadal hormones (estrogens and androgens) of significance in the development of ischemic heart disease.","volume":"149","author":"Furman","year":"1968","journal-title":"Ann N Y Acad Sci"},{"key":"R96-9-20211004","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/0090-6980(77)90229-5","article-title":"Arachidonate-induced thrombosis in mice: effects of gender or testosterone and estradiol administration.","volume":"13","author":"Uzunova","year":"1977","journal-title":"Prostaglandins"},{"key":"R97-9-20211004","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1055\/s-0038-1653405","article-title":"Testosterone potentiation of ionophore and ADP induced platelet aggregation: relationship to arachidonic acid metabolism.","volume":"46","author":"Pilo","year":"1981","journal-title":"Thromb Haemost"},{"key":"R98-9-20211004","doi-asserted-by":"crossref","first-page":"2742","DOI":"10.1161\/01.CIR.91.11.2742","article-title":"Testosterone increases human platelet thromboxane A2 receptor density and aggregation responses.","volume":"91","author":"Ajayi","year":"1995","journal-title":"Circulation"},{"key":"R99-9-20211004","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1093\/qjmed\/hci054","article-title":"Castration reduces platelet thromboxane A2 receptor density and aggregability.","volume":"98","author":"Ajayi","year":"2005","journal-title":"QJM"},{"key":"R100-9-20211004","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.1016\/j.lfs.2007.04.006","article-title":"Modulation of aortic vascular reactivity by sex hormones in a male rat model of metabolic syndrome.","volume":"80","author":"Torres","year":"2007","journal-title":"Life Sci"},{"key":"R101-9-20211004","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1042\/CS20050354","article-title":"Effect of testosterone on ex vivo vascular reactivity in man.","volume":"111","author":"Malkin","year":"2006","journal-title":"Clin Sci (Lond)"},{"key":"R102-9-20211004","doi-asserted-by":"crossref","first-page":"194","DOI":"10.2174\/18715257113119990084","article-title":"Review of newer anticoagulants and anti platelet agents in acute coronary syndrome and cardiovascular diseases.","volume":"11","author":"Gosavi","year":"2013","journal-title":"Cardiovasc Hematol Agents Med Chem"},{"key":"R103-9-20211004","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1053\/euhj.1999.1699","article-title":"Haematocrit, viscosity, erythrocyte sedimentation rate: meta-analyses of prospective studies of coronary heart disease.","volume":"21","author":"Danesh","year":"2000","journal-title":"Eur Heart J"},{"key":"R104-9-20211004","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1093\/ije\/dyt013","article-title":"A U-shaped relationship between haematocrit and mortality in a large prospective cohort study.","volume":"42","author":"Boffetta","year":"2013","journal-title":"Int J Epidemiol"},{"key":"R105-9-20211004","doi-asserted-by":"crossref","first-page":"3588","DOI":"10.1016\/j.ijcard.2013.05.065","article-title":"Association between hematocrit in late adolescence and subsequent myocardial infarction in Swedish men.","volume":"168","author":"Toss","year":"2013","journal-title":"Int J Cardiol"},{"key":"R106-9-20211004","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1208500","article-title":"Cardiovascular events and intensity of treatment in polycythemia vera.","volume":"368","author":"Marchioli","year":"2013","journal-title":"N Engl J Med"},{"key":"R107-9-20211004","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1210\/en.2013-1755","article-title":"Role of androgens in sex differences in cardiac damage during myocardial infarction.","volume":"155","author":"Le","year":"2014","journal-title":"Endocrinology"},{"key":"R108-9-20211004","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1056\/NEJMoa1206168","article-title":"Gonadal steroids and body composition, strength, and sexual function in men.","volume":"369","author":"Finkelstein","year":"2013","journal-title":"N Engl J Med"},{"key":"R109-9-20211004","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1016\/j.biocel.2005.03.002","article-title":"Skeletal muscle and nuclear hormone receptors: implications for cardiovascular and metabolic disease.","volume":"37","author":"Smith","year":"2005","journal-title":"Int J Biochem Cell Biol"},{"key":"R110-9-20211004","doi-asserted-by":"crossref","first-page":"f2865","DOI":"10.1136\/bmj.f2865","article-title":"Restoring invisible and abandoned trials: a call for people to publish the findings.","volume":"346","author":"Doshi","year":"2013","journal-title":"BMJ"},{"key":"R111-9-20211004","doi-asserted-by":"crossref","first-page":"f3601","DOI":"10.1136\/bmj.f3601","article-title":"Restoring the integrity of the clinical trial evidence base.","volume":"346","author":"Loder","year":"2013","journal-title":"BMJ"}],"container-title":["Current Opinion in Endocrinology, Diabetes & Obesity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/01266029-201406000-00009","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,6]],"date-time":"2021-10-06T12:26:09Z","timestamp":1633523169000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01266029-201406000-00009"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,6]]},"references-count":103,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.1097\/med.0000000000000065","relation":{},"ISSN":["1752-296X"],"issn-type":[{"value":"1752-296X","type":"print"}],"subject":[],"published":{"date-parts":[[2014,6]]}}}